Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 5Terminated 4Recruiting 3Active not recruiting 3Withdrawn 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Lymphoid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 57Leukemia, Myeloid, Acute 53Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Myeloproliferative Disorders 24Leukemia 24Primary Myelofibrosis 22Leukemia, Myelomonocytic, Chronic 19Lymphoma, Non-Hodgkin 18Leukemia, Lymphocytic, Chronic, B-Cell 18Hodgkin Disease 16Lymphoma, Follicular 15Multiple Myeloma 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 14Leukemia, Myeloid, Chronic-Phase 14Burkitt Lymphoma 14Polycythemia Vera 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Leukemia, Myeloid, Accelerated Phase 12Lymphoma, Large-Cell, Immunoblastic 11Hematologic Neoplasms 11Congenital Abnormalities 11Blast Crisis 11Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 10Sezary Syndrome 9Recurrence 9Pdgfra-Associated Chronic Eosinophilic Leukemia 9Mycosis Fungoides 9

Interventions

siltuximab 1ruxolitinib 1pelcitoclax 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Thrombocytosis × Myeloid × Clear all
NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Ascentage Pharma Group Inc.

Phase 1/2 Withdrawn
Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase EARLY_PHASE1 Withdrawn
Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡